Luis Gonzalez Orozco
Family Medicine · Des Plaines, ILNPI 1770662637
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,378 and has fallen 73.6% since, to $364 in 2023.
Across 142 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$730
- Bayer$499
- Sanofi-aventis U.S. LLC$486
- Johnson & Johnson$482
- Boehringer Ingelheim$356
- AstraZeneca$288
- plus $448 from 10 others
Across 1,126 payments — averaging $838.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$528K
- Novo Nordisk AS$327K
- Swedish Orphan Biovitrum AB$50K
- Sanofi-aventis U.S. LLC$34K
- Sanofi US Services Inc.$4K
What the payments were for
- Food & beverage$3,283100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $730 |
| Bayer | 12 | $499 |
| Sanofi-aventis U.S. LLC | 17 | $486 |
| Johnson & Johnson | 17 | $482 |
| Boehringer Ingelheim | 14 | $356 |
| AstraZeneca | 17 | $288 |
| Lilly USA, LLC | 7 | $125 |
| Merck | 6 | $87 |
| Pfizer | 4 | $63 |
| Amgen | 3 | $59 |
| Corcept Therapeutics | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| AbbVie | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,289 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 12 | $169 |
| Atorvastatin Calcium | 20 | $161 |
| Metformin Hcl | 25 | $156 |
| Metoprolol Tartrate | 11 | $85 |
| Tamsulosin Hcl | 11 | $82 |
| Hydrochlorothiazide | 14 | $74 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Des Plaines
- Nigam PatelDes Plaines$34K
- Inder SinghDes Plaines$20K
- Frank PhillipsChicago$1.6M
- Peter TothSterling$1.4M
- Bradley TorphyChicago$1.3M
- Jeffrey RoyceRockford$890K
- Anthony AuriemmaWestmont$788K
- Manfred ManGurnee$764K
- Barbara BellarOakbrook Terrace$599K
- Bernie RancheroAltamont$533K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.